The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|January 19, 2015
BRANY announces launch of Protocol Builder™
Web-based and iPad tablet application solution for writing investigator-initiated research protocols
Advertisement
(Lake Success, NY) - BRANY has announced the launch of Protocol Builder™, a first-of-its-kind solution to assist researchers in the development of investigator-initiated research protocols. This web-based application, accessible from any desktop and iPad tablet, is designed to provide expert guidance and a step-by-step process to make protocol development faster and less onerous. Resources necessary to navigate the elaborate regulatory infrastructure that surrounds clinical research in the U.S. are at researchers’ fingertips in this thoughtfully designed application.
“Many investigators find the regulatory and compliance hurdles difficult and time-consuming to navigate when writing protocols,” says Kimberly Irvine, Executive Vice President and Chief Operating Officer at BRANY. “Protocol Builder ensures efficiency and accuracy in developing a complete protocol, ready to submit to the IRB. By following the guided steps in Protocol Builder, investigators will save time and be better able to provide an omission-free protocol for review. Our objective with Protocol Builder is to use technology to empower researchers to achieve their research goals with less effort.”
Utilizing a team of leading experts in both consumer design and investigator-initiated clinical research, BRANY developed a step-by-step intuitive approach to building a protocol. BRANY has deconstructed the complex process of writing research protocols and designed a tool that’s innovative, packed with time-saving features, yet easy to use.
While many institutions provide templates and training to investigators writing investigator-initiated protocols, research shows a high degree of dissatisfaction with these tools. Protocol Builder reduces the complexities in investigator-initiated protocol development and is an excellent tool for both experienced and new investigators.
Protocol Builder is available to institutions through corporate licenses, and to individual investigators through single user licenses. For more information or to sign up for a free demo, please visit
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5